PM
Prof. Michael Holinstat
Head of Cereno's preclinical work at University of Michigan (Scientific Collaborator)
Cereno ScientificTherapeutic Areas
Cereno Scientific Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CS1 | Pulmonary Arterial Hypertension (PAH) | Phase II |
| CS014 | Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD), initial focus on Idiopathic Pulmonary Fibrosis (IPF) | Phase I |
| CS585 | Cardiovascular Disease (potential: Thrombosis prevention without bleeding risk, Pulmonary Hypertension) | Preclinical |